1 PHARMACOKINETICS DR.ABDUL LATIF MAHESAR KING Dr.SAUD UNIVERSITY October 2008D.
-
Upload
loraine-hodges -
Category
Documents
-
view
217 -
download
1
Transcript of 1 PHARMACOKINETICS DR.ABDUL LATIF MAHESAR KING Dr.SAUD UNIVERSITY October 2008D.
2
DRUG ABSORPTION
Is the passage of the drug through body barriers or cell membranes to reach its site of action
3
Mechanism of Drug Movements Across Cell Membrane
Passive diffusion ( simple diffusion )
Active transport
Facilitated diffusion ( need carrier )
Pinocytosis (endocytosis)
4
Passive diffusion Types: a) Aqueous Diffusion ( filtration through the
pores) => water soluble and low molecular weight.
B) Lipid diffusion => lipid soluble and low molecular weight.
6
Charactersa. Commenestb. Non selectivec. Require no energyd. Depends on concentration gradiente. Depends on lipid/water partition coefficientf. Depends on PKa (of drug) and PH ( of the
medium.
7
PKa ( is the dissociation or inization constant) is the PH at which half of the substance is ionized and half is unionized
PH is the ionization of the drug weak acids => best absorbed in stomach( because acid wont be ionized – lipid soluble – best absorption.
Note: strong acids or bases are fully ionized (polar+water soluble)- can not cross cell membrane ,given IV infusion
8
Active transport Relatively not common Against concentration gradient Requires carrier + energy Specific e.g iodides Saturable with receptor Depends on lipid/water coefficient Iron absorption Uptake of levodopa by brain
9
Carrier mediated Along concentration gradient Requires carrier Doesn’t need energy Selective Saturable e.g uptake of glucose .vit.B12 and
intrinsic factor.
10
Endocytosis High molecular weight drugs
There is engulfment of the substrate by the cell e.g vit A,E, D ,K
11
Factors affecting Drug absorption a) Drugs: 1. Molecular weight
2. PKa 3. Lipid water partition coefficient. 4. Drug formulation
12
b) Patient: 1. PH of the gut
2. Rate of the gastric emptying 3. Presence of the food in the gut 4. Intestinal motility (transient time) 5. Surface area available for
absorption 6. Drug interaction
13
c) Food: 1. Reduces absorption e.g
aspirin,pencillin v, tetracyclin, erythromycin
2. Increases absorption e.g propranolol, diazepam, dicoumrol
14
2 .DISTRIBUTION1 .ECF (extra cellular fluid)
Plasma (5% of body weight)Interstitial fluid (16% of body weight)Lymph (1% of body weight)
2. ICF (intracellular fluid)35% sum of fluid contents of all cells in the body
3. Transcellular fluid (2%) cerbrospinal , synovial, peritoneal,pleural, digestive secretion.
15
THE MAJOR BODY FLUID COMPARTMENTS
1.Intravascular(one compartment)in blood (not filtered through endothelium)
2.Extra vascular (2 compartments) i-e blood and interstitial fluid pass endothelium but not cell membranes e.g Nitroglycerine.
3.Extravascular and intracellular( multicompartment)pass endothelium and cell membranes.e.g physostigmine.
16
Factors affecting distribution1. Cardiac output and blood flow. increased
cardiac output increases the distribution2. Physiological properties of the drug3. Permeablity across tissue barrier4. Plasma protein binding with drug5. Tissue binding with drug6. PH7. PKa8. Lipid solubility (fat water partition)
17
Volume of distribution(vd) It is the amount of drug in the body to
the concentration of the drug in blood or plasma.
vd = amount of drug in the body Cp (concentration in plasma)
Increase in Cp ,decreased is the volume of distribution and vice versa
18
Drugs with high volume of distribution
Higher concentration in tissue than in plasma
Relatively lipid soluble
Distributed intracellularly
low molecular weight → easy to cross barrier.
not efficiently removed by the hemodialysis e.g phenyton ,morphine , digoxin,tricyclic anti-depressants
cross BBB or placental barrier easily
19
Drugs with low volume of distribution confined to plasma and interstitial fluids(not tissues)
Distributed in extracellular compartment mostly
High MW ,eg.heparin,insulin ,dextran
these are polar or lipid insoluble drugs e.g carbenicillin, vecuronium,gentamycin
High plasma protein binding e.g warfarin
Don’t cross BBB or placental barrier→ because of lipid insolubility
All skeletal muscle relaxants have low vd.
21
Placental barrier Drugs cross placenta by simple diffusion
lipid soluble drugs readily (easily) enter the fetal blood
In mother if given Morphine → respiratory depression in the fetus Warfarin → hemorrhage ( if taken in the 1st
3months → congenital malformation) Anti-thyroid drugs → neonatal goiter
22
Passage of drugs in to CNS and CSF Controlled by BBB
lipid soluble drugs e.g general anesthetics , CNS depressants, antibiotics chloramphenicol and sulphadiazine.
Inflammation as in meningitis ( in meningitis → permeability is increased e.g penicillin ,gentamycin.
23
Binding of Drugs Tissue binding ( some drugs posses and affinity for certain
tissues and get accumulated in there like :
1. Bone e.g tetracycline and heavy metals such as lead ( which combine with collagen)
2. Fat :drugs like thiopental and ether
3. Salivary and thyroid glands: Iodides
4. Liver: quinacrine ( 300 time more in liver) chloroquine with nucleic acid
5. Hair and Skin: arsenic( combines with keratin)
24
Plasma Protein Binding Albumin:acidic drugs bind with albumin
such as warfarin,phenetoin, aspirin ,sulphonamides
Globulin : Basic drugs such as quinidine ,diazepam
25
Drugs exists in Bound form Unbound or free form Bound drugs
Not available for combination with receptorNo pharmacological actionNot available for metabolismNot available for excretionlong duration of actionmay lead to clinically important drug - drug
interaction
26
Unbound Drug Pharmacologically active Available for metabolism Available for excretion Has short duration of action.
27
Displacement some drugs can compete with each other for the
same site on the plasma protein and displace drugs thus increasing their concentrations to toxic level.
e.g. Warfarin-strong + tolbutamide- weak → hypoglycemia (warfarin is binding where tolbutamide is free +effect)
Aspirin –strong + warfarin-weak → bleeding
29
Resdistribution: resdistribution of the drug from its site of
action to other tissues e.g thiopental
30
METABOLISM Drug metabol(biotransformation) It is the chemical reactions which lead to modification of drugs Sites of metabolism - Hepatic:
microsomes ,mitochondria, cytoplasm
- Extrahepatic: lung ,blood ,skin , GIT,
kidney.
31
Microsomes: Microsomal enzyme system→ mixed
function oxidase → mono-oxigenase. its components:
cytochrome P450Flavinoprotein NADPHMolecular oxygen, Mg
32
Mitochondria:mono-amine oxidase enzyme (MAO)Acetylation
Cytoplasm:Alcohol dehydrogenase
Blood (plasma)EstrasesAmidasesCatechol-o methyltransferases(COMT)
Intestinal Mucosa and Lumen:GIT flora:Glucouronidase ,Asoreductases.
GIT mucosa : Monoamime oxidase (MAO) , Suphatase
34
Phase I Reaction: Make the drug more polar → more water solulble.(oxidation –reduction- hydrolysis) Oxidarion reaction:
introduces functional group (OH,NH2,SH) Can be mirosomal or nonmicrosomal
35
Microsomal: Drug + O2 +NADPH+H→changed drug +H2O +NADPH e.g. 1. Aliphatic hydroxylation
Phenobarbital→hydroxyphenobarbital2. Aromatic hydroxylation
Phenacetin→ 2-hydroxyphenacitin (paracetamol)3. Oxidation of amine
Aniline → nitrobenzene4. sulphoxidation
Parathione → paroxon
36
Non-microsomal: oxidation by soluble enzyme in cytosol or
mitochondria of cells e.g 1. dehydrogenases and oxidases
Ethanol → acetaldehyde → acetic acid.Methanol → formaldehyde → formic acid
CH3CH2OH→ CH3CHO→CH3COOH
2. monoamide oxidase(noradrenaline) 3. Hypoxanthine → xanthine → uric acid
37
Reduction Reactions: Microsomal or non-microsomal
Microsomasl:nitrobenzene → aniline
NO2 →NH2 Non-Microsomal:
Chloral hydrate → trichloroethanol
Hydrolysis:Non-microsomal ONLY
Ester-C-O and amides-C-N Acetylcholine → choline +acetate(ester) Procainamide (lidocaine) (amide)
38
Characteristics of Phase I Products (Result of Drug Metabolism)
1 .Inactivation (abolish the activityOxidation of Phenobarbital and alcohol
Hydrolysis of acetylcholine2 .conversion of active drug to another active one.
Diazepam →oxydiazepamCodeine ,heroin → Morphine
Phenylbutazone → oxyphenylbutazonePropranolol → 4-hydroxypropranolol
3 .conversion of drug to toxic metabolites:Paracetamol → acetaminopen (hepatic toxicity)
Halothane → metabolite hepatotoxicity 4 .Activation of pro-drug
Chloral hydrate → trichloral hydrate 5 .Product might undergo phase II
39
Phase II Conjugation Reaction (Synthetic reaction)
Glucuronide conjugationAminoacid eg.glycine
Acetylation reaction e.g CO-CH3
Sulphate conjugation SO4
Methylation reaction e.g CH3Noradrenaline → adrenaline
ALL is non-microsomal enzyme Except glucouronidation (catalyzed by glucouronyl transferase )
40
Characteristics of Phase II Products
Product = Conjugate Pharmacologically inactive More water soluble→ to be excreted More readily excreted in urine
41
Modulation of Liver Microsomal Enzymes
Induction Inhibition
Liver Microsomal InducersAlcohol
BarbituratesCigarette smoking
PhenytoinRifampicin
SpironalactoneGriseofulvin
42
Enzyme Induction results in Increase metabolism of the inducer Tolerance: decreased pharmacological action of the
drug Increase the metabolism of co-administered drug (drug
interaction)Barbiturate +Warfarin
Phenytoin + Oral contraceptivesRifampicin + Hydrocortisone
Increased metabolite- mediated tissue toxicityParacetamol and phenacetin
As therapy ( phenobarbitone + hyperbilirubinemia)
43
Liver Microsomal InhibitorsCimetidine
Erythromycinketoconazole
MetronidazoleProbenecid
Enzyme inhibition may Retard the metabolism and excretion of the inhibitor
and co-administered drugs
Prolong the action of the inhibitor and co-administered drugs→ increased pharmacological activity.
44
First Pass Metabolism A drug can be metabolized before the drug reaches the
systemic circulation so the amount reaching systemic circulation is less than the amount absorbed
Where ? Liver ,gut wall, lungResult:
low bioavailabilityShort duration of action
How is it given e.g
MorphineSalbutamol
45
4 .EXCRETION Main routes of excretion
Renal excretionBiliary excretion
Minor routes of excretionExhaled air
Salivary secrtetionsSweat MilkTears
46
Renal excretion: Glomerular filtration Active tubular secretion Passive tubular reabsorption Alteration in tubular PH
e.g : gentamycin , ampicillin ,benzylpencillin ,digoxin
Contraindicaited: in case of renal failure
in case of elderly
47
Glomerular filtration Only free drug (not bound to albumin) Low molecular weight drug( below 20000) renal plasma flow = 600ml /min GFR 20% of renal plasma flow = 125 ml/min
48
Active Tubular secretion: Characters:
Selective
Require energy carrier Against concentration gardient Clearance to plasma protein bound drugsTypes
System for acidic drugsSystem for basic drugs
49
System for Acidic Drugs:e.g. of acidic drugs:
salicylates,sulphonamides,penicillin,glucouronide conjugate, sulphate conjugate.
Blocked by : probenicid (inhibitor)→ carrier will carry this drug so ,
acidic drugs → long duration of action + blocker will excertion.
System for Basic Drugs:e.g
catecholamines,atropine ,morphine ,quinine ,neostigmine.
50
Passive tubular reabsorption
Non ionized form (lipid soluble) can be reabsorbed back into systemic circulation
and excretion will be low
Ionized drugs are poorly reabsorbed and so rapidly excereted.
51
Alteration in urine PHUrine is normally slightly acidic and favors
excretion of basic drugsAcidification of urine→ increased excretion
of basic drugsAlkalization of urine → increased excretion
of acidic drugs.
52
Acidification of urine:by
ammonium chlorideascorbic acid
Alkalization of urineby
Sodium bicarbonateSodium lactateSodium citrate.
53
Biliary excretion
Is important for some drugs that are metabolized in the liver
e.g :digoxin
Biliary excretion is useful in treating biliary infection
It plays a role in the removal of conjugated metabolites particularly glucouronides
54
Enterohepatic CirculationBile passes into the intestine where drug if lipid soluble is
reabsorbed again and cycles is repeated.
Glucouronides are hydrolyzed in intestine liberating free drugs that can be reabsorbed back
This prolongs the action the druge.g. morphine , ethinyl estradiol ,
thyroxine